Compare FA & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FA | STOK |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2021 | 2019 |
| Metric | FA | STOK |
|---|---|---|
| Price | $12.37 | $33.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $15.67 | ★ $39.20 |
| AVG Volume (30 Days) | ★ 914.0K | 648.1K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 72.97 | ★ 92.73 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,574,389,000.00 | $184,420,000.00 |
| Revenue This Year | $8.42 | N/A |
| Revenue Next Year | $7.26 | $77.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 83.02 | ★ 404.50 |
| 52 Week Low | $8.82 | $8.30 |
| 52 Week High | $19.01 | $40.22 |
| Indicator | FA | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 55.77 | 45.21 |
| Support Level | $12.10 | $32.70 |
| Resistance Level | $12.78 | $35.06 |
| Average True Range (ATR) | 0.58 | 1.60 |
| MACD | 0.10 | -0.06 |
| Stochastic Oscillator | 57.29 | 31.16 |
First Advantage Corp is a provider of software and data in the Human Resources technology industry. The company provides end-to-end identity solutions, criminal background screening, credential verifications, drug and health screening, and continuous risk monitoring. It combines AI-powered proprietary technology platforms with proprietary data, primary source data, and third-party data. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. The company generates maximum revenue from the Sterling segment, which provides similar services as compared to First Advantage's Americas and International segments on a global basis. Geographically, the company generates the majority of its revenue from the United States.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.